Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
German Center for Diabetes Research (DZD), Munich, Germany.
Med. 2021 Oct 8;2(10):1120-1137. doi: 10.1016/j.medj.2021.08.003. Epub 2021 Sep 15.
In this review, we bring our personal experiences to showcase insulin from its breakthrough discovery as a life-saving drug 100 years ago to its uncovering as the autoantigen and potential cause of type 1 diabetes and eventually as an opportunity to prevent autoimmune diabetes. The work covers the birth of insulin to treat patients, which is now 100 years ago, the development of human insulin, insulin analogues, devices, and the way into automated insulin delivery, the realization that insulin is the primary autoimmune target of type 1 diabetes in children, novel approaches of immunotherapy using insulin for immune tolerance induction, the possible limitations of insulin immunotherapy, and an outlook how modern vaccines could remove the need for another 100 years of insulin therapy.
在这篇综述中,我们结合个人经验,回顾了胰岛素从 100 年前作为一种救命药物的突破性发现,到揭示其作为自身抗原和 1 型糖尿病潜在病因,最终成为预防自身免疫性糖尿病的机会。这项工作涵盖了胰岛素用于治疗患者的诞生,这是 100 年前的事了,还有人胰岛素、胰岛素类似物、设备的发展,以及自动化胰岛素输送的方式,认识到胰岛素是儿童 1 型糖尿病的主要自身免疫靶标,使用胰岛素进行免疫耐受诱导的免疫疗法的新方法,胰岛素免疫疗法的可能局限性,以及现代疫苗如何消除未来 100 年胰岛素治疗需求的展望。